Literature DB >> 9491062

Clinical predictors of acute response with olanzapine in psychotic mood disorders.

C A Zarate1, R Narendran, M Tohen, J J Greaney, A Berman, S Pike, A Madrid.   

Abstract

BACKGROUND: In controlled studies of patients with schizophrenia, the atypical antipsychotic olanzapine has been shown to be more effective in the treatment of positive and negative symptoms compared with haloperidol at doses of 10 mg/day. However, little is known about the efficacy of olanzapine in patients with psychotic mood disorders. The purpose of this study was to assess the efficacy of olanzapine in the treatment of these psychotic mood disorders in comparison with nonaffective psychotic disorders and to identify clinical factors associated with olanzapine response.
METHOD: In a naturalistic setting, by reviewing medical records, we assessed response to olanzapine and factors associated with response to olanzapine in 150 consecutive patients newly treated with the drug at a nonprofit academic psychiatric hospital.
RESULTS: Patients displaying a moderate-to-marked response to olanzapine were more likely to be younger; be female; receive a diagnosis of bipolar disorder; and have a shorter duration of illness, shorter length of stay prior to olanzapine, and longer duration of trial.
CONCLUSION: Olanzapine may be a useful alternative or adjunctive treatment for patients with bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491062     DOI: 10.4088/jcp.v59n0106

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Atypical antipsychotic drugs in nonschizophrenic psychiatric disorders.

Authors:  C A Zarate; M Vemuri; S Cavanagh; M Land
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 2.  Functional impairment and cognition in bipolar disorder.

Authors:  C A Zarate; M Tohen; M Land; S Cavanagh
Journal:  Psychiatr Q       Date:  2000

3.  Clinical predictors of ketamine response in treatment-resistant major depression.

Authors:  Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

4.  The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study.

Authors:  Jihyung Hong; Catherine Reed; Diego Novick; Josep Maria Haro; Frank Windmeijer; Martin Knapp
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 5.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Atypical antipsychotics and mood stabilization in bipolar disorder.

Authors:  Paolo Brambilla; Francesco Barale; Jair C Soares
Journal:  Psychopharmacology (Berl)       Date:  2003-02-27       Impact factor: 4.530

7.  The social, psychopathological and consumer context of rate of symptom improvement in acute mania.

Authors:  Jim van Os; Inge van Rossum; Maarten Boomsma; Eduard Vieta; Iris Goetz; Catherine Reed; Josep Maria Haro
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-06-27       Impact factor: 4.328

8.  Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care.

Authors:  Raphael J. Leo; Paula Del Regno
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

9.  Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group.

Authors:  Lei Xu; Yunrong Lu; Ying Yang; Yanping Zheng; Fang Chen; Zheng Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2015-05-25       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.